Accuray's philosophy is to personalize treatments to exactly fit the patient. Senior Director of Marketing Andrew Delao explains this philosophy in a conversation with Greg Freiherr at ASTRO 2018.
VIDEO: Explaining Boron Neutron Capture Therapy for Targeted Cancer Radiotherapy
Bruce Bauer, Ph.D., CEO of TAE Life Sciences. The company is developing boron neutron capture therapy (BNCT) as a new radiation therapy for cancer. A patient is first infused with a non-toxic boron-10 compound, which selectively accumulates in tumor tissue. A neutron beam is then focused on the tumor and the neutrons are captured by the boron and causes emission of alpha radiation particles within the tumor. Alpha particles have a a very short range, so this helps spare surrounding healthy tissue from radiation damage.
Historically, BNCT clinical studies have been carried out using boronophenylalanine (BPA) and neutrons derived from the core of a nuclear reactor. While the clinical outcomes have been encouraging, the availability of better boron-10 compounds and access to a neutron source posed a significant barrier to clinical research and adoption of BNCT as a practical cancer therapy.
There is now a renaissance in BNCT with the availability of new accelerator-based neutrons sources and novel synthesis of boron-10 target drugs, allowing clinical research to expand with the goal to have BNCT available as a new treatment option for patients.
The secondary radiation reaction from BNCT, with cellular-level precision, spares more healthy tissues and can potentially treat cancers that otherwise have few treatment options.
The system requires a neutron accelerator, but this is smaller than a proton system and operates at much lower energy, so the shielding requirement is much lower, cutting construction costs.
This is an example of how artificial intelligence (AI) can help improve patient care by pulling together patient data from numerous sources and then select medical records that are specific to a patient’s diagnosis and treatment for a defined disease state. This is Siemens’ AI-Pathway Companion introduced at the Radiological Society Of North America (RSNA) 2018 meeting. In this examples. A prostate cancer patient has all their data on a single time line that can be accessed by single clicks on the points to open reports, images, procedures or labs.
At the end of the time line it integrates AI driven clinical decision support that recommends the next course of action based on clinical guidelines. The guidelines cited can also be opened for review by the clinician.
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the American Society for Radiation Oncology (ASTRO) 2018 conference. The overview includes new technologies for proton therapy, MRI-guded radiation therapy, PET-guided radiotherapy, brachytherapy, SRS quality assurance, 3-D printing and mobile connectivity to the oncology information system.
An interview with A. M. Niser Syed, M.D., medical director, radiation oncology and endocurietherapy, MemorialCare Cancer Institute, Long Beach, Calif. At the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting, he presented a study of 1,200 patients using a single session of intra-operative radiation therapy (IORT) using the Xoft X-ray emitting brachytherapy system.
Aadel Chaudhuri, M.D., assistant professor of radiation oncology, Washington University, St. Louis, Mo., explains his research on using blood tests to collect circulating lung tumor cells to assess their response to radiotherapy. This use of liquid biopsies can eliminate the need for invasive needle biopsies. He spoke on this topic at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting.
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation that needs to be delivered to treat the tumor and spare surrounding healthy tissue. Javier Torres-Roca, M.D., associate professor of radiation oncology, Moffit Cancer Center, and co-founder of the genomics company Cvergenx, spoke on this topic at the ASTRO 2018 conference.
Interview with Peyman Kabolizadeh, M.D., the medical director of Beaumont Proton Therapy Center, Royal Oak, Mich. He explains how proton therapy fits into Beaumont's overall strategy of cancer treatment. He also explains Beaumont's development of proton arc therapy that is in development. He spoke on these topics at that ASTRO 2018 meeting.
Kristin Higgins, M.D., medical director of radiation oncology at the Emory Clinic at the Winship Cancer Institute, and associate professor, Department of Radiation Oncology, Emory University School of Medicine, explains how the use of a novel positron-emission tomography, computed tomography (PET-CT) system combined with a linac in a single gantry might offer a new approach to real-time adaptive therapy. She spoke to ITN at the 2018 ASTRO conference.
Read the article about the technology displayed at ASTRO 2018 — Biology Guided Radiotherapy May Improve Physician Confidence in Treatment of Multiple Tumors
Elizabeth Chabner-Thompson, M.D., MPH, radiation oncologist, Northern Westchester Hospital, Northwell Health, Mt. Kisco, N.Y., and CEO of Masthead, explains an FDA-cleared bra she designed for improved patient positioning of women undergoing radiation therapy. She spoke to ITN at the 2018 ASTRO conference.
Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology (ASTRO), gives an update on where things are at for radiotherapy reimbursement, CMS conversion factors and MACRA. She spoke on this topic at the 2018 ASTRO conference.
Scott Schwartz, M.D., interventional radiologist and program director for IR residencies and the vascular and interventional radiology fellowship at Henry Ford Hospital, explains how the department uses Yttrium-90 (Y90) embolization therapy to treat liver cancer.
Related Articles on Y-90 Radiotherapy:
Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute, describes the benefits the department has realized from using the first FDA-approved magnetic resonance imaging (MRI)-guided radiation therapy system to allow real-time treatment tracking.
Register to view a webinar on the ViewRay MRI-guided radiation therapy system.
Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, describes how the department uses magnetic resonance imaging (MRI) scans to create synthetic computed tomography (CT) images for use in radiation therapy treatment planning.
Also watch the VIDEOs Using Advanced CT to Enhance Radiation Therapy Planning and MRI-Guided Radiation Therapy Trial for Pancreatic Cancer, which also feature Glide-Hurst.
Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, describes how the department uses advanced computed tomography (CT) software and techniques to improve radiation therapy treatment plans.
Related Content With Glide-Hurst:
Carri Glide-Hurst, Ph.D., and Benjamin Movsas, M.D., discuss Henry Ford Hospital's involvement in a national clinical trial assessing the effectiveness of magnetic resonance imaging (MRI)-guided radiation therapy in pancreatic cancer.
Watch the related VIDEO: Clinical Use of the ViewRay MRIdian Linac System at Henry Ford — Interview with Benjamin Movsas, M.D.
Register to view a webinar on the ViewRay MRI-guided radiation therapy system.
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Group and head of the Duke medical physics graduate program. He spoke on this topic at the American Association of Physicists in Medicine (AAPM) 2018 meeting.
A discussion with Kevin Moore, Ph.D., DABR, deputy director of medical physics and associate professor, University of California San Diego, about his daily clinical use of an artificial intelligence treatment planning software. He spoke on this at the American Association of Physicists in Medicine (AAPM) 2018 meeting.
Also watch the VIDEO: The Impact of Artificial Intelligence on Radiation Therapy — an interview with Steve Jiang, Ph.D.
ITN Editor Dave Fornell takes a tour of some of the innovative new technologies on the expo floor at the 2018 American Association of Physicists in Medicine (AAPM) meeting.
A discussion with Mahadevappa Mahesh, Ph.D., FAAPM, FACR, FACMP, FSCCT, professor of radiology and cardiology and chief physicist at Johns Hopkins, Baltimore. He also serves as treasurer for the American Association of Physicists in Medicine (AAPM) and spoke to ITN at the 2018 meeting.
Watch the VIDEO Radiation Dose Monitoring in Medical Imaging, an interview with Mahesh at the 2016 Radiological Society of North America (RSNA) annual meeting.
A discussion with Matthew Freeman, Ph.D., scientist at Los Alamos National Laboratory, New Mexico. He spoke about his research using direct proton imaging on the treatment table without the need for other external or on-board imaging systems. He spoke at the 2018 American Association of Physicists in Medicine (AAPM) meeting.
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada. He spoke on this topic in sessions at the American Association of Physicists in Medicine (AAPM) 2018 meeting. He explains radiomics and how it can be used in both medical imaging and radiation therapy.
Read the related article "Hidden Information Behind Imaging Tests for Cancer May Unlock New Approaches to Radiation Therapy."
Read the related article "Computer Program Beats Physicians at Brain Cancer Diagnoses."
Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Group and head of the Duke medical physics graduate program, explained this new program at the American Association of Physicists in Medicine (AAPM) 2018 meeting.
This is an example of how Cherenkov radiation glow can be collected with image intensifier cameras during radiotherapy to show the exact location of the beam and the amount of dose delivered. This can be used to quickly verify everything matches the treatment plan and dosimetry. This video was shot in the booth of DoseOptics at the 2018 American Association of Physicists in Medicine (AAPM). The company is developing this technology and hopes to submit it to U.S. Food and Drug Administration(FDA) for review in the next year.
A discussion with Steve Jiang, Ph.D., director of the medical artificial intelligence and automation lab and vice-chair of the Department of Radiation Oncology, University of Texas Southwestern. He spoke in sessions at AAPM 2018 about how AI will change treatment planning, radiation oncology and medical imaging.
Watch the VIDEO: Real-world Implementation of Deep Learning for Treatment Planning — a discussion with Kevin Moore, Ph.D., DABR, deputy director of medical physics and associate professor, University of California San Diego, about his daily clinical use of an artificial intelligence treatment planning software.
American Association of Physicists in Medicine (AAPM) President Bruce Thomadsen, M.D., professor of medical physics at the University of Wisconsin, Madison, discusses the future direction of medical physics in a changing healthcare environment at the 2018 AAPM meeting.
Chris Toth, president, global commercial and field operations for Varian, takes a tour of Varian’s new product introductions and major initiatives highlighted at ASTRO 2017. These include:
• The Halcyon system, a new platform for cancer treatment that simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). Halcyon is a powerfully intuitive platform designed to help improve and strengthen the fight against cancer and enable access to high quality care anywhere in the world.
• The 360 Oncology care management platform, designed to integrate and coordinate patient care across the entire treatment and post-treatment journey. 360 Oncology brings together in a single platform, radiation, medical and surgical oncology, social services, primary care physicians, as well as the patient, to facilitate true collaboration and coordination.
• The latest release of Varian’s Eclipse treatment planning software, incorporating both Multi-Criteria Optimization (MCO) and Graphics Processing Unit (GPU) Support. MCO enables planners to look at tradeoffs in a treatment plan when different clinical criteria are varied, greatly enhancing control over optimization. GPU support decreases the dose calculation and inverse planning optimization times, providing a significant leap forward in speed.
• HyperArc high definition radiotherapy, technology that unlocks the potential of non-coplanar treatment strategies to usher in a new era of precision in the delivery of stereotactic radiosurgery (SRS).
For more information: www.varian.com
William Hall, M.D., radiation oncologist in the Department of Radiation Oncology at PeaceHealth St. Joseph Medical Center in Bellingham, Wash., discusses study results presented at theAmerican Society of Radiation Oncology (ASTRO) 2016. Video courtesy of Dr. Hall. You can read Dr. Hall's article on this topic, Breast Cancer Radiation Planning, here.
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key themes of the 2017 Annual Meeting and the issues ASTRO will focus on going into 2018.
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains how research presented at the 2017 Annual Meeting was chosen to reflect new trends in radiation therapy.
The new Visicoil MR is a helically-wound, flexible linear fiducial marker. The Visicoil MR hollow core design and multiple sizes mitigates the CT artifact often created by traditional gold seeds, offering you clearer visualization of the tissue to aid in faster and more accurate contouring. Visicoil MR's linear flexible design fixates and remains stable in soft tissue, giving you the confidence in accurate marker localization. Visicoil MR is available in some of the smallest needle sizes available for fiducial markers, including 21g and 22g needles. The benefits of smaller needles are improved patient safety and comfort during implantation. The smaller needles may also allow for faster CT sim after implant and ultimately treatment for your patients. The new Visicoil MR with enhanced MRI visibility allows you to see the marker more easily in MRI, both in T1 and T2. This makes for easier and faster MR/CT fusion.
Melissa Martin, MS, president of the American Association of Physicists in Medicine (AAPM), discusses her vision of the role of medical physics in healthcare and highlights the association's initiatives at the 2017 AAPM annual meeting in Denver.
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the clinical applications and practical aspects of operating a proton therapy center at the 2017 American Association of Physicists in Medicine (AAPM) annual meeting.
Join Chris Toth, president, Oncology Systems Americas, for a look at Varian’s new product introductions and major initiatives highlighted at ASTRO this year:
- The 360 Oncology care management platform, the first software system designed to integrate and coordinate integrates relevant health information so cancer patients and their care teams can collaborate on the best care. 360 Oncology brings together in a single platform, radiation, medical and surgical oncology, social services, primary care physicians, as well as the patient, to facilitate true collaborative and coordinated care.
- HyperArc high definition radiotherapy, technology that unlocks the potential of using highly non-coplanar treatment strategies to usher in a new era of precision. HyperArc is designed to automate and simplify sophisticated treatments such as stereotactic radiosurgery (SRS), and make them available to more cancer patients around the world.
- Varian’s cyber-security initiative, which is transforming the company’s software platforms to help maximize the security of patient information, maintain the integrity of treatment delivery, and enhance clinical uptime by helping defend against cyber-attacks.
Learn more about myQA, IBA’s unique platform that connects QA applications, people, and know-how through a central database and the Cloud. It offers full support throughout all of your QA, and enables you access to the different software modules and all of your data from one intuitive interface – anywhere and anytime.
Accuray recently unveiled the company’s newest innovation, the Radixact Treatment Delivery System, a uniquely smart, fully integrated treatment delivery, treatment planning and data management system. Hear from the Accuray team about this new, next-generation TomoTherapy platform, as well as how recent innovations to the CyberKnife platform reduce treatment time while providing leading-edge motion tracking and real-time beam adjustment. Discover how Accuray systems can help clinicians deliver precise tumor treatments with confidence.
Rachael Bennett, clinical analyst for MD Buyline, discusses trends in radiation oncology at ASTRO 2016.
ASTRO Chairman of the Board David C. Beyer, MD, FASTRO, discusses the current trends in radiation oncology, key trends presented at this year's conference, and achieving value, and opportunities to improve value, in the treatment of prostate cancer.
Patient QA Efficiency with Dolphin presented at AAPM 2016 IBA booth. Dolphin Online Ready is released and in clinical use for pre-treatment QA.
AAPM President Bruce Curran, MEng, FAAPM, FACMP, FACR, discusses the key topics at the 2016 meeting of the American Association of Physicists in Medicine. Topics included the advancement of radiomics in medical imaging for quantification for evidence-based clinical decision making in cancer, and improving how quality assurance is done in radiation therapy.